Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 23-24/2020

01.12.2020 | editorial

Double trouble: severe aortic stenosis and cardiac amyloidosis

verfasst von: MD Christian Nitsche, MD Julia Mascherbauer

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Aortic stenosis (AS) as well as cardiac amyloidosis (CA) are prevalent conditions in old patients. The combination of both AS and CA has recently been identified to occur in a significant number of patients scheduled for aortic valve replacement. Age alone, however, does not fully explain the frequent overlap of the two pathologies as the prevalence of CA in individuals >80 years in the general population has been described to be <1% [ 1]. …
Literatur
1.
Zurück zum Zitat Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2. CrossRef Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2. CrossRef
3.
Zurück zum Zitat Audet A, Côté N, Couture C, et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology. 2012;61:610–9. CrossRef Audet A, Côté N, Couture C, et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology. 2012;61:610–9. CrossRef
5.
Zurück zum Zitat Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12. CrossRef Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12. CrossRef
8.
Zurück zum Zitat Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. CrossRef Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. CrossRef
11.
Zurück zum Zitat Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16. CrossRef Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16. CrossRef
12.
Zurück zum Zitat Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. CrossRef Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. CrossRef
13.
Zurück zum Zitat Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. CrossRef Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. CrossRef
Metadaten
Titel
Double trouble: severe aortic stenosis and cardiac amyloidosis
verfasst von
MD Christian Nitsche
MD Julia Mascherbauer
Publikationsdatum
01.12.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01787-7